Consultation on a draft Global action plan to address antimicrobial resistance

The questionnaire is divided into four sections. The questions are broadly framed and intended to give you the opportunity to enter into some depth and explain your organization's viewpoint. While only questions marked with * are mandatory, we would appreciate answers to as many as possible. Where a choice of answer needs to be selected please highlight your answer.

Before answering the questions, please refer to our list of supporting documents.


About you

1. Name of individual respondent*
   (deleted)
2. Email address* (preference for official email addresses)
   (deleted)
3. Are you authorised to represent your organization or interest group?* Y _ √ _ N ___
4. Organization Name*
   National Health and Family Planning commission of China
5. Address of the organization*
   NO. 1 XIZHIMENWAINANLU, DISTRICT XICHENG, BEIJING, CHINA
6. Organization website (if available)
   http://www.nhfpc.gov.cn
7. Country*
   CHINA
8. Type of Organization*
   • Government department, ministry or agency
9. Main sector of interest
   • Human health
10. Would you like to be added to our mailing list to receive updates on the development of the global action plan?* Y_√_ N __

General questions

1. From the perspective of your organization, what are the most important areas of concern in AMR?
   
   Surveillance of AMR, Administration of clinical use of Antibiotics, Communications: Awareness, understanding and education

2. Is your organization currently involved in work related to AMR? Y_√_ N __
   If Yes, How?
   
   (1) launched “special campaign for antibiotic rational use in hospitals” every year from 2011.
   
   (2) In 2005, established “MOH Center for Antibacterial Surveillance”、“China Antimicrobial Resistance Surveillance System” and “Chinese Monitoring Network for Rational Use of Drug”, to monitor the clinical use of Antibiotics.
   
   (3) establish a administrative system to provide legal and managerial basis for clinical use of antibiotics. e.g. “Guiding Principles of Clinical Use of Antibiotics”、“Administrative Regulations for Nosocomial Infections”、“Administrative Regulations for Prescription”、“Notification on Strengthening Management of Clinical Use of Antibiotics”、“National essential drug list”“Administrative Regulations for Clinical Use of Antibiotics” etc.

Questions about the draft global action plan outline document

Before the WHA resolution was adopted, two WHO AMR Strategic Technical Advisory Group (STAG) meetings were held in anticipation, which included members plus a large number of representatives from other organizations. These meetings identified key issues, concerns and led to the development of a draft outline.

As this consultation progresses and stakeholder meetings are held, the secretariat will harvest and incorporate the input into the draft global action plan.

1. How would you rate your understanding of WHO’s intention in the development of a global action plan to address AMR?
Very good__ Good_ √ _ Fair__ Poor__

Additional comments

2. From the perspective of your organization, are the major issues relating to AMR outlined in the draft global action plan? Y_ √ _ N ___

If No, what additional issues need to be addressed?

Questions on the ‘Building blocks’ described in the draft outline.

You will notice, the global action plan has been constructed around “building blocks” in recognition that different countries will have different starting points. In this situation, countries can choose building blocks to concentrate upon. Each building block specified has been identified as a key area where specific attention, planning and work are needed to achieve progress in addressing AMR. Through questions in this section, we would like to hear your opinions on these building blocks in more detail.

I. Building block-1: Increasing awareness and understanding about AMR and of the actions and changes needed

a) What do you consider to be the main issues under this priority?
Lack of awareness about AMR in general public

b) What are the main actions that needs to be done -- and who are the main actors/stakeholders who need to take action -- to go beyond the status quo?
Education -- policy makers -- general public, health-care workers

c) What steps have already been taken to address this priority? (please provide references where possible)
Train health-care workers to use of antibiotics.
Propaganda the rational use of antibiotics among general public, e.g. Hand hygiene.

d) What are concrete and measurable indicators of progress for this priority? (Including, for example, global and national goals to be achieved within 2, 5 and 10 years)
II. Building block-2: Identifying the most important approaches for preventing development of infections and the steps needed to move beyond guidance to more effective implementation of such approaches

a) What do you consider to be the main issues under this priority?
Lack of awareness in general public and healthcare workers

b) What are the main actions that needs to be done -- and who are the main actors/stakeholders who need to take action -- to go beyond the status quo?
Health promotion and education -- policy makers -- general public, health-care workers

c) What significant work has already been done to address this? (please provide references where possible)
Propaganda the rational use of antibiotics among general public, e.g. Hand hygiene.

d) What are concrete and measurable indicators of progress for this priority? (Including, for example, global and national goals to be achieved within 2, 5 and 10 years)
exchange of practice among regional level

III. Building block-3: Optimizing the use of existing antimicrobials for human and animal health and in agriculture

a) What do you consider to be the main issues under this priority?
Surveillance of AMR

b) What are the main actions that needs to be done -- and who are the main actors/stakeholders who need to take action -- to go beyond the status quo?
Set up coordinating mechanism – WHO

c) What steps have already been taken to address this priority? (please provide references where possible)
launched “special campaign for antibiotic rational use in hospitals” every year from 2011.

In 2005, established “MOH Center for Antibacterial Surveillance”、“China Antimicrobial Resistance Surveillance System” and “Chinese Monitoring Network for Rational Use of Drug”, to monitor the clinical use of Antibiotics.
establish a administrative system to provide legal and managerial basis for clinical use of antibiotics. e.g. “Guiding Principles of Clinical Use of Antibiotics”、“Administrative Regulations for Nosocomial Infections”、“Administrative Regulations for Prescription”、“Notification on Strengthening Management of Clinical Use of Antibiotics”、“National essential drug list”、“Administrative Regulations for Clinical Use of Antibiotics” etc.
d) What are concrete and measurable indicators of progress for this priority? (Including, for example, global and national goals to be achieved within 2, 5 and 10 years)

WHO leadership and support

IV. Building block-4: Identifying and closing critical gaps in knowledge needed to address AMR

a) What do you consider to be the main issues under this priority?

Laboratory capacity

b) What are the main actions that needs to be done -- and who are the main actors/stakeholders who need to take action -- to go beyond the status quo?

Training – policy makers – health-care workers

c) What steps have already been taken to address this priority? (please provide references where possible)

In 2005, established “MOH Center for Antibacterial Surveillance”、“China Antimicrobial Resistance Surveillance System” and “Chinese Monitoring Network for Rational Use of Drug”, to monitor the clinical use of Antibiotics.

establish a administrative system to provide legal and managerial basis for clinical use of antibiotics. e.g. “Guiding Principles of Clinical Use of Antibiotics”、“Administrative Regulations for Nosocomial Infections”、“Administrative Regulations for Prescription”、“Notification on Strengthening Management of Clinical Use of Antibiotics”、“National essential drug list” “Administrative Regulations for Clinical Use of Antibiotics” etc.

d) What are concrete and measurable indicators of progress for this priority? (Including, for example, global and national goals to be achieved within 2, 5 and 10 years)

WHO support

V. Building block-5: Developing an innovative and sustainable approach to develop and distribute critical products and technologies needed to address AMR

a) What do you consider to be the main issues under this priority?

b) What are the main actions that needs to be done -- and who are the main actors/stakeholders who need to take action -- to go beyond the status quo?

c) What steps have already been taken to address this priority? (please provide references where possible)
d) What are concrete and measurable indicators of progress for this priority? (Including, for example, global and national goals to be achieved within 2, 5 and 10 years)

VI. Building block-6: Assessing the long term economic, developmental and social costs and implications of AMR as a basis for sustainable investment and action

a) What do you consider to be the main issues under this priority?

b) What are the main actions that needs to be done -- and who are the main actors/stakeholders who need to take action -- to go beyond the status quo?

c) What steps have already been taken to address this priority? (please provide references where possible)

d) What are concrete and measurable indicators of progress for this priority? (Including, for example, global and national goals to be achieved within 2, 5 and 10 years)

Concluding questions

3. What contribution would your organization be able to make in implementing the global action plan?

Exchange experience

4. Additional input that you feel would be facilitate development of the GAP.

none